Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

T1D Exchange

- PMLiVE

J&J gets FDA panel backing for canagliflozin

Moves ahead of BMS/AZ’s Forxiga in race for US approval as first in new class of diabetes drug

- PMLiVE

Novo Nordisk creates all-diabetes pro-cycling team

Team Novo Nordisk includes more than 100 cyclists, triathletes and runners with diabetes

- PMLiVE

Boehringer and Lilly close in on empagliflozin filing

But amend diabetes alliance after Boehringer drops basal insulin

- PMLiVE

Lilly delivers upbeat earnings forecast for 2013

New products will offset generic competition for Alimta, Zyprexa, Cymbalta and Evista

- PMLiVE

Lilly pays $29m to settle foreign bribery charges

US Securities and Exchange Commission charges centre on activities in Russia, China, Brazil and Poland

- PMLiVE

Lilly stops tabalumab trial in arthritis on efficacy grounds

Will take a charge of around $20m to $35m

- PMLiVE

Lilly plans another trial for Alzheimer’s hope solanezumab

Presses on with another late-stage study for the drug

- PMLiVE

New UK managing director for Lilly

Dr Jean-Michel Cossery takes over from Ramona Sequeira

- PMLiVE

Lilly taps Strides Arcolab for cancer generics

Aims to expand its presence in emerging pharmaceutical markets

- PMLiVE

Novo Nordisk says Ryzodeg nears Japanese approval

Combination of Tresiba and NovoRapid expected to compete with Sanofi’s Lantus

- PMLiVE

Merz, Lilly and Daiichi-Sankyo breach ABPI code

Pharma companies 'named and shamed' for inappropriate marketing in the UK

- PMLiVE

Depth perception: diabetes in India

Using digital, pharma can engage with diabetes patients in India and build a 3D image of their needs

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links